Teachers Retirement System of The State of Kentucky Has $2.67 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Teachers Retirement System of The State of Kentucky lessened its position in Exelixis, Inc. (NASDAQ:EXEL) by 2.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 102,776 shares of the biotechnology company’s stock after selling 2,550 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Exelixis were worth $2,667,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Covestor Ltd grew its stake in Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 341 shares in the last quarter. Resonant Capital Advisors LLC boosted its holdings in shares of Exelixis by 3.6% during the second quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock worth $309,000 after purchasing an additional 477 shares during the period. Cornercap Investment Counsel Inc. grew its position in Exelixis by 1.1% during the second quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock valued at $1,135,000 after purchasing an additional 539 shares in the last quarter. Creative Planning increased its stake in Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock valued at $1,611,000 after buying an additional 548 shares during the period. Finally, Advisors Asset Management Inc. lifted its position in Exelixis by 3.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock worth $515,000 after buying an additional 609 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on EXEL. Truist Financial boosted their price target on shares of Exelixis from $33.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Bank of America upped their target price on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Stephens raised their price target on Exelixis from $23.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Wells Fargo & Company boosted their price target on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Finally, Piper Sandler raised their price objective on shares of Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $31.47.

Exelixis Stock Performance

Exelixis stock opened at $35.03 on Monday. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $36.97. The firm has a market capitalization of $10.00 billion, a PE ratio of 22.46, a PEG ratio of 0.89 and a beta of 0.52. The business’s 50-day simple moving average is $32.66 and its 200-day simple moving average is $27.18.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. During the same period in the previous year, the business posted $0.10 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. Research analysts forecast that Exelixis, Inc. will post 1.69 earnings per share for the current year.

Insider Activity at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Dana Aftab sold 1,162 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 339,736 shares of company stock worth $11,508,610 in the last ninety days. 2.85% of the stock is currently owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.